Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test Combined Screening- Roche (SSDW) is 5 days.

What are the prerequisites for the test Combined Screening- Roche (SSDW)

  • Age: The test is recommended for pregnant women between the ages of 18 and 45.
  • Gestational Age: The test can be performed between 9 weeks and 14 weeks of pregnancy.
  • Singleton Pregnancy: The test is suitable for women carrying a single fetus.
  • Not Suitable for: Women with multiple pregnancies (twins, triplets, etc.), women who have undergone IVF with egg donation, and women with a history of chromosomal abnormalities.

What are the measure values for the test Combined Screening- Roche (SSDW)

Measure Value
Alpha-fetoprotein (AFP) 0.5 - 14 ng/mL
Free Beta-human chorionic gonadotropin (Free β-hCG) 0.0 - 5.0 MoM
Unconjugated estriol (uE3) 0.3 - 3.0 ng/mL
hCGβ 0.0 - 5.0 MoM

What does this test Combined Screening- Roche (SSDW) identify?

Combined Screening- Roche (SSDW)

The Combined Screening- Roche test, also known as the SSDW test, is a screening test used to identify certain genetic disorders in newborns. This test looks for markers associated with disorders such as Down syndrome, trisomy 18, and neural tube defects.

The test involves analyzing a blood sample from the mother, typically taken between 9 and 13 weeks of pregnancy, and combining this with an ultrasound measurement of the fetus's nuchal translucency. The results are then used to calculate the risk of the fetus having one of the genetic disorders.

If the test results indicate a high risk, further diagnostic testing such as amniocentesis or chorionic villus sampling may be recommended to confirm the presence of the disorder.

Why is this test Combined Screening- Roche (SSDW) taken?

Combined Screening- Roche (SSDW) test is taken to assess the risk of certain chromosomal abnormalities in a developing fetus, specifically Down syndrome (Trisomy 21), Trisomy 18, and Trisomy 13. This test combines a maternal blood test with an ultrasound to provide an estimate of the likelihood that a fetus may have one of these chromosomal abnormalities.

The maternal blood test measures the levels of certain proteins and hormones that may indicate an increased risk of chromosomal abnormalities. The ultrasound looks at the thickness of the nuchal translucency (a fluid-filled space at the back of the fetus's neck) and the presence of a nasal bone, which can also be indicators of an increased risk.

By combining these two tests, healthcare providers can provide expectant parents with more information about the likelihood of their fetus having a chromosomal abnormality. This can help parents make informed decisions about further testing or preparation for the birth of a child with special needs.

No FAQs available.

Customer Google Rating